Simons F E
Department of Pediatrics, University of Manitoba, Winnipeg, Canada.
J Allergy Clin Immunol. 1992 Oct;90(4 Pt 2):705-15. doi: 10.1016/0091-6749(92)90156-v.
Most first-generation and second-generation H1-receptor antagonists have readily demonstrable antiallergic effects in vitro, although high concentrations of some of the medications are required to inhibit mediator secretion from mast cells or basophils. These antiallergic effects can also be seen in vivo in skin, nasal, lung, and ocular challenge studies. Some H1-receptor antagonists appear to have an antiallergic effect in one organ but not in another. In many in vivo studies, doses of H1-receptor antagonists three or more times higher than those required for H1 blockade must be given to achieve the antiallergic effect. It would be premature to attempt to reclassify the H1 antagonists according to their antiallergic properties because these properties have not been investigated fully and their relative contribution to the overall therapeutic effectiveness of each H1 receptor antagonist is unknown.
大多数第一代和第二代H1受体拮抗剂在体外具有易于证明的抗过敏作用,尽管需要某些药物的高浓度来抑制肥大细胞或嗜碱性粒细胞的介质分泌。这些抗过敏作用在皮肤、鼻腔、肺部和眼部激发试验的体内研究中也可见到。一些H1受体拮抗剂似乎在一个器官中有抗过敏作用,而在另一个器官中则没有。在许多体内研究中,必须给予比H1阻断所需剂量高三倍或更多倍的H1受体拮抗剂剂量才能达到抗过敏作用。根据其抗过敏特性对H1拮抗剂进行重新分类还为时过早,因为这些特性尚未得到充分研究,并且它们对每种H1受体拮抗剂总体治疗效果的相对贡献尚不清楚。